Aquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 29,814 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Peter Boyd sold 29,814 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $124,324.38. Following the sale, the insider owned 338,509 shares in the company, valued at $1,411,582.53. This trade represents a 8.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Aquestive Therapeutics Trading Up 2.5%

Shares of Aquestive Therapeutics stock traded up $0.11 on Wednesday, hitting $4.31. The stock had a trading volume of 1,170,828 shares, compared to its average volume of 5,614,740. The stock has a market cap of $525.38 million, a price-to-earnings ratio of -5.52 and a beta of 1.61. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $7.55. The company’s 50 day moving average price is $4.13 and its 200 day moving average price is $5.22.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million. Analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on AQST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.80.

Key Stories Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 30.8% during the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after purchasing an additional 1,333,627 shares during the period. Federated Hermes Inc. increased its stake in Aquestive Therapeutics by 159.4% in the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after buying an additional 1,249,044 shares during the period. BNP Paribas Financial Markets raised its position in Aquestive Therapeutics by 6,233.4% during the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock worth $7,569,000 after buying an additional 1,153,175 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth $5,918,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Aquestive Therapeutics by 804.6% in the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock worth $7,678,000 after acquiring an additional 1,057,145 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.